Randomized
(n=226)

Randomized to receive Nicardipine
(n=110)
Received study drug as assigned
(n=109)

Patient withdrew consent and lost to follow-up (n=1)

Analysed
• included in safety analysis (n=110)
• included in primary endpoint analysis (n=109)

Randomized to receive Labetalol
(n=116)
Received study drug as assigned
(n=116)

Patient withdrew consent and lost to follow-up (n=2)

Analysed
• included in safety analysis (n=116)
• included in primary endpoint analysis (n=114)